MEDA acquires a US respiratory company
Meda has signed an agreement to acquire the US development company Acton Pharmaceuticals, Inc. (“Acton”) including the proprietary product Aerospan. Aerospan is an inhaler for the treatment of asthma that contains the active substance Flunisolide. The product is approved by the FDA and has shown in clinical studies to have a high deposition of active drug in the airways as a result of a built-in inhalation chamber (called a “spacer”).
In a randomized double-blind placebo-controlled study, published in the Annals of Allergy, Asthma & Immunology, Aerospan show no significant negative effect on linear growth in children with asthma. This is an important feature of the Aerospan product. FDA has recently approved the addition of data from this study in the prescribing information.
The launch of Aerospan is planned to the beginning of 2014. The total US market for inhaled asthma products containing a mono-corticosteroid is estimated at 2 billion USD. The use of spacers is increasing very rapidly. In some markets, more than one third of patients who use inhaled corticosteroids also use a spacer. Aerospan is the only product registered in the US market with a built-in spacer. Meda’ s target is to reach a minimum of 2 billion SEK in sales within 5 years.
The purchase price for Acton amounts to 135 million USD. In addition, there is a milestone payment of 10 million USD and royalty based milestones. The acquisition is expected to close during the fourth quarter and is subject to customary closing conditions and the approval of the US competition authorities. Existing credit facilities will fund the acquisition.
"The acquisition of Acton is a unique opportunity to gain access to a newly registered product in the US market. Aerospan is within Meda’s primary focus area - Respiratory and is based on a new technology," says Anders Lönner, CEO of Meda AB. "Paired with Dymista, this gives us a clear profile in our highest priority area as well as important marketing synergies. Aerospan will be launched in the US market in the beginning of next year and other major markets will follow.”
For further inquiries, please contact:
Anders Lönner, CEO ph: +46 8-630 1972
Anders Larnholt, Vice President Corporate Development & IR ph: +46 709-458 878
Paula Treutiger, Investor Relations ph: +46 733-666 599
MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in more than 120 countries worldwide and the company is represented by its own organizations in over 55 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.
This press release is not an offer to sell or a solicitation to buy shares in Meda. This press release also contains certain forward-looking statements with respect to certain future events and Meda’s potential financial performance. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts, and may sometimes include words such as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”, “forecast”, “believe” or other words of similar meaning. These forward looking statements reflect the current expectations on future events of the management at the time such statements are made, but are made subject to a number of risks and uncertainties. In the event such risks or uncertainties materialize, Meda’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research and product development, manufacturing and commercialization, the impact of competitive products, patents, legal challenges, government regulation and approval, Meda’s ability to secure new products for commercialization and/or development and other risks and uncertainties detailed from time to time in Meda AB’s interim or annual reports, prospectuses or press releases. Listeners and readers are cautioned that no forward-looking statement is a guarantee of future performance and that actual result could differ materially from those contained in the forward-looking statements. Meda does not intend, nor undertakes, to update any such forward looking statements.